Dupilumab for patchy hair loss with scalp inflammation
Treatments studied
Part of Skin clinical trials.
This Phase 2 trial tests dupilumab (an injection medicine) to regrow hair in people with alopecia areata, a condition where the immune system attacks hair follicles. It may help by reducing the immune-related inflammation linked to hair loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and able to sign consent and follow study visits.
- You must have alopecia areata (at least 6 months) or nearly all scalp hair loss (alopecia totalis/universalis).
- Your blood tests must meet specific ranges (for blood cells, liver tests, kidney function, and hemoglobin).
- If you can become pregnant, you must have a negative pregnancy test and use reliable birth control during the study and for 28 days after the last dose.
- You must not be pregnant or breastfeeding.
- Your hair loss type must fit alopecia areata, not other likely causes like scarring or traction.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies dupilumab (an injection medicine) to help grow hair in children and teens with alopecia areata, an autoimmune hair-loss condition. It aims to see whether the treatment improves hair regrowth compared with usual care over the study period.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
This study tests whether a new drug called LY4005130 can help regrow hair in adults with severe alopecia areata (an autoimmune condition causing patchy or widespread hair loss). The trial is looking for people who have lost a significant amount of hair and haven't seen it grow back on its own for at least 6 months.
This study tests a pill called baricitinib for people with active alopecia areata that started within the last 3 months. Baricitinib is a type of medication called a JAK inhibitor, which can help calm the immune system and stop hair loss.
This trial tests if microneedling with either lactic acid, vitamin D3, or a steroid cream helps regrow hair in people with patchy alopecia areata (small bald spots).
This study tests an investigational oral medication (deuruxolitinib) for adolescents with severe alopecia areata (hair loss). It aims to see if it can help hair regrow safely.
Hear when a new Alopecia Areata trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.